Claims for Patent: 7,718,634

Summary for Patent: 7,718,634

Title:	Method of treatment using bisphosphonic acid
Abstract:	The present invention refers to a pharmaceutical composition of a bisphosphonic acid or salt thereof, and an excipient thereof, and a method of treating disorder characterized by pathologically increased bone resorption comprising orally administering at least 150% of the expected efficious daily dose of a bisphosphonic acid or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients thereof and administering the dose at a period of one two or three consecutive days per month.
Inventor(s):	Bauss; Frieder (Neuhofen, DE), Pichler; Bernhard (Ketsch, DE), Turley; Stephen (Bottmingen, CH)
Assignee:	Hoffman-La Roche Inc. (Nutley, NJ)
Application Number:	12/139,587
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,718,634
Patent Claims:	1. A method for treating or inhibiting postmenopausal osteoporosis in a postmenopausal woman in need of treatment or inhibition of postmenopausal osteoporosis by administration of a pharmaceutically acceptable salt of ibandronic acid, comprising: (a) commencing the administration of the pharmaceutically acceptable salt of ibandronic acid by orally administering to the postmenopausal woman, on a single day, a first dose in the form of a tablet, wherein the tablet comprises an amount of the pharmaceutically acceptable salt of ibandronic acid that is equivalent to about 150 mg of ibandronic acid; and (b) continuing the administration by orally administering, once monthly on a single day, a tablet comprising an amount of the pharmaceutically acceptable salt of ibandronic acid that is equivalent to about 150 mg of ibandronic acid. 2. The method of claim 1, wherein the pharmaceutically acceptable salt is a sodium salt of ibandronic acid. 3. The method of claim 2 wherein the pharmaceutically acceptable sodium salt is a monosodium salt of ibandronic acid. 4. The method of claim 3 wherein the pharmaceutically acceptable monosodium salt of ibandronic acid is a monohydrate. 5. A method for treating or inhibiting postmenopausal osteoporosis in a postmenopausal woman in need of treatment or inhibition of postmenopausal osteoporosis by administration of a pharmaceutically acceptable salt of ibandronic acid, consisting essentially of orally administering to the postmenopausal woman, once monthly on a single day, a tablet comprising an amount of the pharmaceutically acceptable salt of ibandronic acid that is equivalent to about 150 mg of ibandronic acid. 6. The method of claim 5, wherein the pharmaceutically acceptable salt is a sodium salt of ibandronic acid. 7. The method of claim 6 wherein the pharmaceutically acceptable sodium salt is a monosodium salt of ibandronic acid. 8. The method of claim 7 wherein the pharmaceutically acceptable monosodium salt of ibandronic acid is a monohydrate. 9. A method for treating or inhibiting postmenopausal osteoporosis in a postmenopausal woman in need of treatment or inhibition of postmenopausal osteoporosis by administration of a pharmaceutically acceptable salt of risedronic acid, comprising: (a) commencing the administration of the pharmaceutically acceptable salt of risedronic acid by orally administering to the postmenopausal woman, on a single day, a first dose in the form of a tablet, wherein the tablet comprises an amount of the pharmaceutically acceptable salt of risedronic acid that is equivalent to about 150 mg of risedronic acid; and (b) continuing the administration by orally administering, once monthly on a single day, a tablet comprising an amount of the pharmaceutically acceptable salt of risedronic acid that is equivalent to about 150 mg of risedronic acid. 10. A method for treating or inhibiting postmenopausal osteoporosis in a postmenopausal woman in need of treatment or inhibition of postmenopausal osteoporosis by administration of a pharmaceutically acceptable salt of risedronic acid, consisting essentially of orally administering to the postmenopausal woman, once monthly on a single day, a tablet comprising an amount of the pharmaceutically acceptable salt of risedronic acid that is equivalent to about 150 mg of risedronic acid.